The Pathway Behind the Number
To understand what TMAO means in relation to atrial fibrillation, start with the route that produces the number in a blood test. TMAO is often called a gut-microbiome metabolite, but that label compresses several steps: nutrients enter the pathway, microbes make trimethylamine, the liver converts it, and the kidneys help remove the final product. The useful question is therefore not only “How high is TMAO?” It is “Which combination of production, conversion, and clearance produced that level?”
That question matters because the same circulating concentration can arise from different biological routes. A person may have more substrate available, a microbial community with greater capacity to make trimethylamine, a different rate of hepatic conversion, or less renal clearance. Those possibilities do not carry identical implications for AF. A blood value is a pathway output; it is not a direct label attached to one bacterium, one food, or one disease mechanism.
From dietary substrates to circulating TMAO
The pathway begins with compounds such as choline, phosphatidylcholine, and L-carnitine. These are nutrients or nutrient-related molecules that can be handled by gut microbes. Microbial metabolism converts them into trimethylamine, abbreviated TMA. TMA is not yet TMAO. It is an intermediate that leaves the microbial part of the pathway and becomes a substrate for the host.
The liver then oxidizes TMA through flavin monooxygenases, or FMOs, especially FMO3, to produce trimethylamine N-oxide. Once formed, TMAO circulates through the bloodstream and can be measured. This division of labor is central to interpreting the molecule. The gut supplies one part of the chemistry; the host liver performs another. Calling TMAO “microbial” describes where the pathway begins, not where every step occurs.
The JCI study makes this multi-stage structure concrete in mice. A choline-supplemented diet changed the gut microbial community and increased expression of CutC/D, the catalytic machinery for microbial choline TMA lyase. That result identifies a pathway node: microbial capacity to make TMA from choline. It does not mean that CutC/D alone determines the TMAO level. The amount of choline available, the rest of the microbial community, hepatic conversion, and removal from the circulation still matter.
The pathway can be represented as a sequence, but it is not a simple conveyor belt with one speed. Each stage can vary, and the stages interact with the physiological setting in which TMAO is measured.
The diagram separates three kinds of control that are easy to merge in casual discussion. Microbial composition and function influence how much TMA can be generated. Hepatic conversion influences how much TMA becomes TMAO. Renal function influences how much TMAO remains in circulation. The final measured level reflects all three, along with the amount of substrate entering the pathway.
This is why “change the microbiome” is not a complete intervention description. A microbial intervention might reduce the conversion of choline to TMA, but the effect on TMAO would still depend on hepatic activity and clearance. Conversely, a high TMAO value does not establish that microbial production is unusually high. The value may be elevated because the body is removing the metabolite less efficiently.
The distinction also prevents a common category error. A metabolite can be produced through a microbial pathway without being a direct census of the microbes responsible. The evidence can show that a diet changes microbial diversity or CutC/D expression in mice, yet still fail to identify a single organism as the cause of a person’s TMAO level. A measured concentration tells us that the pathway has produced and retained a quantity of TMAO. It does not, by itself, reveal which link contributed most.
Three distinctions make this easier to see. First, a substrate is not the same thing as an exposure dose to the heart. Choline or L-carnitine may enter the pathway, but the amount reaching microbial enzymes depends on how the pathway is organized in the gut. Second, a microbial capacity is not the same thing as a microbial identity. CutC/D expression tells researchers that the community has more or less capacity for a particular conversion; it does not by itself identify a single responsible species or prove that the same change occurs in people. Third, TMA is not TMAO. TMA is the microbial intermediate, while TMAO is the host-converted product that appears in the circulation. A study that changes one of these compounds is testing a different point in the pathway from a study that measures only the final product.
These distinctions are especially important when a study describes the “gut microbiome” as if it were one organ with one output. The microbiome is a community whose functional capacity can change without every member changing in the same direction. In the mouse study, choline supplementation changed microbial diversity and increased CutC/D messenger RNA, while IMC attenuated many of those changes. That is evidence that the diet and the inhibitor affected the pathway as a system. It is not a map from one named taxon to one human AF event, and it does not establish that every way of altering the microbiome would have the same result.
The host side has its own separation of roles. Hepatic FMO activity determines how efficiently TMA is converted to TMAO, but the resulting blood concentration still depends on how quickly TMAO is removed. A change in liver conversion could raise TMAO even if microbial TMA production stayed constant. A change in renal clearance could raise it even if neither microbial activity nor hepatic conversion changed. If only the final concentration is measured, those routes can look identical.
A useful thought experiment follows directly from the pathway. Imagine two people with the same measured TMAO level. In one, the level reflects greater TMA generation and normal clearance. In the other, it reflects ordinary production but impaired removal. The blood test alone does not distinguish them. If both are later compared for AF, a difference in outcome could be attributed incorrectly to the metabolite when it partly reflects the underlying physiological state. The thought experiment does not show that TMAO is merely a bystander; it shows why the causal question must specify which part of the pathway is being changed.
Why the same blood value can mean different things
The liver is one source of variation. In the JCI mouse experiments, female CREM-IbΔC-X mice had higher circulating TMAO than male mice, including on a chow diet, consistent with higher expression of hepatic FMO3 in female mice. This is an important detail for interpreting the experimental system: the same microbial substrate can lead to different circulating TMAO levels when host conversion differs. It is not a general rule that can be transferred directly to human patients, but it demonstrates why host biology belongs in the pathway model.
The kidney is another source, and it creates a particularly important interpretive boundary for cardiovascular research. TMAO is cleared by the kidney. When estimated glomerular filtration rate, or eGFR, is lower, a higher circulating level may reflect reduced removal as well as greater production. If reduced kidney function also raises the risk of cardiovascular events, then TMAO can appear strongly associated with an outcome partly because both are connected to renal physiology.
The PREVEND cohort study illustrates the problem without directly answering the AF question. Among 5,469 participants followed for a median of 8.3 years, 322 people died. Participants in the highest TMAO quartile had a crude 1.86-fold higher mortality risk than those in the lowest quartile. The association persisted through several risk-factor adjustments, but after further adjustment for urinary albumin excretion and eGFR, the hazard ratio was 1.15 with a 95% confidence interval from 0.81 to 1.64, and the trend was no longer statistically significant.
The result does not prove that kidney function explains every TMAO association. The study’s authors also considered the possibility of mutual causation: impaired kidney function may raise TMAO by reducing clearance, while TMAO or related processes may contribute to kidney dysfunction. The cohort used one baseline TMAO measurement, lacked dietary information, and was predominantly Caucasian. Those limits matter. The study is not evidence that TMAO has no biological role; it is evidence that a prognostic association cannot be interpreted safely without asking how the metabolite is cleared.
The renal example exposes three different questions that are often hidden inside one statistical result. The first is measurement: does a high value indicate more production, less removal, or both? The second is causation: does TMAO contribute to the outcome, or does the illness that raises the outcome also change TMAO? The third is transportability: would the same association appear in a population with different renal function? A model can adjust for eGFR and make the association smaller, but that change does not, by itself, answer all three questions.
That lesson applies to AF even though the cohort’s endpoint was mortality. If a TMAO–AF study adjusts for eGFR, the adjustment may reduce confounding, reveal mediation, or remove part of a pathway that is genuinely related to both the metabolite and arrhythmia. It cannot, by itself, tell us whether kidney function is merely a nuisance variable, an intermediate step, or part of a feedback loop. The causal interpretation requires a biological model and study design that can distinguish those possibilities.
For example, suppose a study finds that TMAO is higher among people who later develop AF. If those participants also have lower eGFR, the result could mean that TMAO is part of a chain involving renal dysfunction and atrial vulnerability. It could mean that TMAO is a marker of the same systemic condition that affects both kidneys and atria. It could also mean that the study’s single baseline measurement does not capture changing exposure over time. These are competing explanations, not interchangeable wordings for the same conclusion.
The practical consequence is not that researchers should discard TMAO whenever kidney function is relevant. It is that a useful study must make the pathway visible. It should characterize renal function alongside TMAO, state whether participants have preserved or impaired clearance, define the AF outcome precisely, and avoid presenting one adjusted coefficient as the whole causal story. Repeated measurements may help distinguish a persistent pathway signal from a transient value, although the source cohort’s single baseline measurement cannot answer that question. The more a study wants to claim that TMAO itself is a modifiable driver, the more it must show what happened to the pathway and to the clinical outcome after an intentional change.
The same reasoning applies to the mouse evidence, even though its conditions are more controlled. A difference in circulating TMAO between female and male mice can reveal host conversion as a source of variation, but it does not establish a sex-specific human threshold. A choline diet can increase TMAO and alter the atrial phenotype in a model with a particular genetic susceptibility, but it does not show that every elevation in every human population follows the same route. Control improves causal inference; it does not erase the need to ask which parts of the system were controlled and which were not.
This is also why a single threshold is difficult to justify. A TMAO value measured in someone with preserved renal function may not be comparable to the same value in someone with impaired clearance. The two values could represent different balances between production and removal. If the clinical setting also differs, the outcome question changes again. The number cannot be separated from the pathway and the population that generated it.
The pathway model therefore changes what we should expect from TMAO research. It allows us to ask whether a microbial enzyme, a host conversion step, or renal handling is the most relevant intervention point. It also tells us what a study must measure if it wants to make a causal claim: not only circulating TMAO, but the exposure, the relevant pathway activity, host physiology, and the AF outcome under study.
Most importantly, the pathway explains why plausibility is not proof. The route from substrate to TMAO can be biologically coherent, and a blood level can track risk, without every elevated measurement being the cause of AF. The next question is whether deliberately changing this route changes atrial susceptibility. That requires controlled exposure and pathway inhibition, not another reading of the same composite signal.